Metronidazole B.Braun (Metronidazole)

Metronidazole is taken up by susceptible anaerobic organisms, where its nitro group is enzymatically reduced to reactive nitro radicals. These radicals damage DNA and inhibit nucleic acid synthesis, leading to loss of cellular integrity and death of the bacterial or protozoal cell.

The dosage of Metronidazole B.Braun is individualized by the prescribing clinician based on the type and severity of infection, patient weight, renal and hepatic function, and other clinical factors. No fixed regimen is provided here; the prescriber sets the appropriate dose.

The pregnancy safety category for Metronidazole is not definitively established. It is generally avoided during the first trimester unless the benefit outweighs the potential risk. Use during lactation should be considered carefully, as the drug is excreted in breast milk; a healthcare professional should evaluate the situation.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team will then provide pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Metronidazole is often preferred for strict anaerobic bacteria because of its targeted mechanism and oral‑to‑IV flexibility. Alternatives such as clindamycin or beta‑lactam/beta‑lactamase inhibitor combinations may be used, but they can have broader spectra and different side‑effect profiles. Choice depends on pathogen susceptibility, infection site, and patient tolerance.

Metronidazole B.Braun should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If a temporary temperature excursion occurs, consult the product’s stability data before use.

The product is supplied as an injectable solution for intravenous infusion. It is reconstituted with the appropriate diluent, inspected for clarity, and administered over the prescribed period, typically via a peripheral or central line under aseptic conditions. Administration details are provided by the prescribing clinician.

Serious adverse events include peripheral neuropathy, which may be irreversible if not recognized early, seizures, severe hypersensitivity reactions such as Stevens‑Johnson syndrome, hepatotoxicity, and profound neutropenia. Patients should be monitored for neurological symptoms, skin reactions, and liver function abnormalities during therapy.

Metronidazole B.Braun is contraindicated in individuals with known hypersensitivity to metronidazole or other nitroimidazole derivatives. Caution is advised for patients with severe hepatic impairment, those receiving disulfiram, and patients with a history of seizures or severe neurological disorders. The drug should be avoided in such cases unless the clinical benefit justifies the risk.